Metronomic Capecitabine in Stage III Gastric Cancer
Status:
RECRUITING
Trial end date:
2029-03-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.